SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Translational Research Studies.

Trial Profile

SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Translational Research Studies.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Aug 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Additional lead investigator identified as reported by ClinicalTrials.gov, last updated 3-2-2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top